当前位置： SCI文献检索 > BMC CANCER期刊下所有文献 > The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis.

The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis.

Abstract：

BACKGROUND:Invasive micropapillary carcinoma (IMPC) of the breast is a rare variant of invasive ductal carcinoma (IDC). The prognosis of IMPC compared with that of IDC remains controversial; we conducted a meta-analysis to evaluate the prognostic difference between IMPC and IDC. METHODS:We searched the PubMed, Cochrane Library, and EMBASE databases for relevant studies comparing overall survival (OS), disease-specific survival (DSS), relapse-free survival (RFS), local-regional recurrence-free survival (LRRFS) or distant metastasis-free survival (DMFS) rates between IMPC and IDC. Fixed-effect and random-effect models were utilized based on the heterogeneity of the eligible studies. Heterogeneity was further evaluated by subgroup and sensitivity analyses. RESULTS:Fourteen studies with 1888 IMPC patients were included in the meta-analysis. The summarized odds ratio (OR) and 95% confidence interval (95% CI) was calculated to estimate the prognostic difference between IMPC and IDC. IMPC patients showed an unfavorable prognosis for RFS (OR; 2.04; 95% CI: 1.63-2.55) and LRRFS (OR: 2.82; 95% CI: 1.90-4.17) compared with IDC. However, no significant difference was observed in OS (OR: 0.93; 95% CI: 0.78-1.10), DSS (OR: 1.16; 95% CI: 0.95-1.40) and DMFS (OR: 0.95; 95% CI: 0.67-1.35) between IMPC and IDC. No obvious statistical heterogeneity was detected, except for DSS. Funnel plots and Egger's tests did not reveal publication bias, except for RFS. CONCLUSIONS:This analysis showed that IMPC patients have a higher rate of loco-regional recurrence than IDC patients. However, OS, DSS and DMFS were not significantly different between IMPC and IDC. These results could help clinicians select therapeutic and follow-up strategies for IMPC patients.

journal_name

BMC Cancer

journal_title

BMC cancer

authors

Wu Y,Zhang N,Yang Q

doi

10.1186/s12885-017-3855-7

subject

Has Abstract

pub_date

2017-12-11 00:00:00

pages

839

issue

1

issn

1471-2407

pii

10.1186/s12885-017-3855-7

journal_volume

17

pub_type

杂志文章,meta分析

相关文献

BMC CANCER文献大全
  • A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.

    abstract：BACKGROUND:Standard therapy for borderline-resectable pancreatic cancer in the UK is surgery with adjuvant chemotherapy, but rates of resection with clear margins are unsatisfactory and overall survival remains poor. Meta-analysis of single-arm studies shows the potential of neo-adjuvant chemo-radiotherapy but the rela...

    journal_title：BMC cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1186/s12885-016-2765-4

    authors： Holyoake DL,Ward E,Grose D,McIntosh D,Sebag-Montefiore D,Radhakrishna G,Patel N,Silva M,Mukherjee S,Strauss VY,Odondi L,Fokas E,Melcher A,Hawkins MA

    更新日期：2016-09-13 00:00:00

  • Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma.

    abstract：BACKGROUND:Hemostatic alterations occur during the development of cancer. Plasma D-dimer is a hypercoagulability and fibrinolytic system marker that is increased in patients with various solid tumours. The aim of this study was to evaluate the hemostatic status of nasopharyngeal carcinoma (NPC) patients by assessing pl...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/1471-2407-14-583

    authors： Chen WH,Tang LQ,Wang FW,Li CP,Tian XP,Huang XX,Mai SJ,Liao YJ,Deng HX,Chen QY,Liu H,Zhang L,Guo SS,Liu LT,Yan SM,Li CF,Zhang JP,Liu Q,Liu XW,Liu LZ,Mai HQ,Zeng MS,Xie D

    更新日期：2014-08-10 00:00:00

  • Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma.

    abstract：BACKGROUND:New biomarkers are needed for the prognosis of advanced colorectal cancer, which remains incurable by conventional treatments. O6-methylguanine DNA methyltransferase (MGMT) methylation and protein expression have been related to colorectal cancer treatment failure and tumor progression. Moreover, the presenc...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/1471-2407-14-511

    authors： Oliver JA,Ortiz R,Melguizo C,Alvarez PJ,Gómez-Millán J,Prados J

    更新日期：2014-07-11 00:00:00

  • M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas.

    abstract：BACKGROUND:Recent progress in molecular analysis has advanced the understanding of medulloblastoma (MB) and is anticipated to facilitate management of the disease. MB is composed of 4 molecular subgroups: WNT, SHH, Group 3, and Group 4. Macrophages play a crucial role in the tumor microenvironment; however, the functio...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/s12885-018-4457-8

    authors： Lee C,Lee J,Choi SA,Kim SK,Wang KC,Park SH,Kim SH,Lee JY,Phi JH

    更新日期：2018-05-08 00:00:00

  • Extramammary Paget's disease with the appearance of a nodule: a case report.

    abstract：BACKGROUND:Extramammary Paget's disease (EMPD) remains a rare condition with only a limited number of cases reported in the literature. EMPD is mainly composed of intraepidermal Paget cells, and possesses variable clinical behaviors and histological appearances, leading to difficulty in the diagnosis of this disease. ...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/1471-2407-10-405

    authors： Wang X,Yang W,Yang J

    更新日期：2010-08-04 00:00:00

  • Investigating the performance and cost-effectiveness of the simple ultrasound-based rules compared to the risk of malignancy index in the diagnosis of ovarian cancer (SUBSONiC-study): protocol of a prospective multicenter cohort study in the Netherlands.

    abstract：BACKGROUND:Estimating the risk of malignancy is essential in the management of adnexal masses. An accurate differential diagnosis between benign and malignant masses will reduce morbidity and costs due to unnecessary operations, and will improve referral to a gynecologic oncologist for specialized cancer care, which im...

    journal_title：BMC cancer

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1186/s12885-015-1319-5

    authors： Meys EM,Rutten IJ,Kruitwagen RF,Slangen BF,Bergmans MG,Mertens HJ,Nolting E,Boskamp D,Beets-Tan RG,van Gorp T

    更新日期：2015-06-26 00:00:00

  • Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.

    abstract：BACKGROUND:Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). This study was conducted to assess the efficacy and safety of apatinib in patients with non-triple-negative metastatic breast cancer who had received prior chemotherapy for their metastatic disease. MET...

    journal_title：BMC cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1186/1471-2407-14-820

    authors： Hu X,Cao J,Hu W,Wu C,Pan Y,Cai L,Tong Z,Wang S,Li J,Wang Z,Wang B,Chen X,Yu H

    更新日期：2014-11-07 00:00:00

  • Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo.

    abstract：BACKGROUND:Glioblastoma is the most common and most aggressive form of malignant glioma and is very difficult to treat. Controlling tumour cell invasion and angiogenesis is essential to improve the prognosis of glioblastoma patients. Since constitutive activation of nuclear factor-κB (NF-κB) is necessary for tumour pro...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/1471-2407-12-453

    authors： Nakabayashi H,Shimizu K

    更新日期：2012-10-05 00:00:00

  • The role of RhoC in epithelial-to-mesenchymal transition of ovarian carcinoma cells.

    abstract：BACKGROUND:RhoC is a small G protein/GTPase and involved in tumor mobility, invasion and metastasis. Previously, up-regulated RhoC expression is found to play an important role in ovarian carcinogenesis and subsequent progression by modulating proliferation, apoptosis, migration and invasion. METHODS:We transfected Rh...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/1471-2407-14-477

    authors： Gou WF,Zhao Y,Lu H,Yang XF,Xiu YL,Zhao S,Liu JM,Zhu ZT,Sun HZ,Liu YP,Xu F,Takano Y,Zheng HC

    更新日期：2014-07-01 00:00:00

  • Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.

    abstract：BACKGROUND:Pancreatic cancer is poorly characterized at genetic and non-genetic levels. The current study evaluates in a large cohort of patients the prognostic relevance of molecular subtypes and key transcription factors in pancreatic ductal adenocarcinoma (PDAC). METHODS:We performed gene expression analysis of who...

    journal_title：BMC cancer

    pub_type： 临床试验,杂志文章

    doi：10.1186/s12885-016-2540-6

    authors： Janky R,Binda MM,Allemeersch J,Van den Broeck A,Govaere O,Swinnen JV,Roskams T,Aerts S,Topal B

    更新日期：2016-08-12 00:00:00

  • CC-Chemokine receptor CCR7: a key molecule for lymph node metastasis in esophageal squamous cell carcinoma.

    abstract：BACKGROUND:CC-chemokine receptor 7 (CCR7), a known lymph node homing receptor for immune cells, has been reported as a key molecule in lymph node metastasis. We hypothesized a clinicopathological correlation and functional causality between CCR7 expression and lymph node metastasis in patients with esophageal squamous ...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/1471-2407-14-291

    authors： Irino T,Takeuchi H,Matsuda S,Saikawa Y,Kawakubo H,Wada N,Takahashi T,Nakamura R,Fukuda K,Omori T,Kitagawa Y

    更新日期：2014-04-26 00:00:00

  • MicroRNA-143 down-regulates Hexokinase 2 in colon cancer cells.

    abstract：BACKGROUND:MicroRNAs (miRNAs) are well recognized as gene regulators and have been implicated in the regulation of development as well as human diseases. miR-143 is located at a fragile site on chromosome 5 frequently deleted in cancer, and has been reported to be down-regulated in several cancers including colon cance...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/1471-2407-12-232

    authors： Gregersen LH,Jacobsen A,Frankel LB,Wen J,Krogh A,Lund AH

    更新日期：2012-06-12 00:00:00

  • Adherence to hormone therapy among women with breast cancer.

    abstract：BACKGROUND:Despite the excellent results obtained with hormone therapy, the long treatment period and the side effects associated with its use make patient adherence difficult. Moreover, certain aspects of health care can mitigate or exacerbate non-adherence. This study aimed to identify the factors associated with adh...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/1471-2407-14-397

    authors： Brito C,Portela MC,de Vasconcellos MT

    更新日期：2014-06-03 00:00:00

  • "Unique trend" and "contradictory trend" in discrimination of primary synchronous lung cancer and metastatic lung cancer.

    abstract：BACKGROUND:Distinguishing between multiple primary lung cancers and metastatic tumors is often difficult when the tumor histology is same. Since genomic instability is a common feature of cancer, we hypothesized that independently arising neoplasms in an individual patient would exhibit measurable genomic variation, en...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/1471-2407-13-467

    authors： Shen C,Xu H,Liu L,Zhou Y,Chen D,Du H,Han Z,Che G

    更新日期：2013-10-09 00:00:00

  • Screening of the DNA mismatch repair genes MLH1, MSH2 and MSH6 in a Greek cohort of Lynch syndrome suspected families.

    abstract：BACKGROUND:Germline mutations in the DNA mismatch repair genes predispose to Lynch syndrome, thus conferring a high relative risk of colorectal and endometrial cancer. The MLH1, MSH2 and MSH6 mutational spectrum reported so far involves minor alterations scattered throughout their coding regions as well as large genomi...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/1471-2407-10-544

    authors： Thodi G,Fostira F,Sandaltzopoulos R,Nasioulas G,Grivas A,Boukovinas I,Mylonaki M,Panopoulos C,Magic MB,Fountzilas G,Yannoukakos D

    更新日期：2010-10-11 00:00:00

  • A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).

    abstract：BACKGROUND:Bevacizumab, an antibody neutralizing Vascular Endothelial Growth Factor (VEGF), is licensed for the management of patients with advanced colon cancer. However, tumor biomarkers identifying the molecular tumor subsets most amenable to angiogenesis modulation are lacking. METHODS:We profiled expession of 245...

    journal_title：BMC cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1186/1471-2407-14-111

    authors： Pentheroudakis G,Kotoula V,Fountzilas E,Kouvatseas G,Basdanis G,Xanthakis I,Makatsoris T,Charalambous E,Papamichael D,Samantas E,Papakostas P,Bafaloukos D,Razis E,Christodoulou C,Varthalitis I,Pavlidis N,Fountzilas G

    更新日期：2014-02-20 00:00:00

  • Long-term follow-up results of simultaneous integrated or late course accelerated boost with external beam radiotherapy to vaginal cuff for high risk cervical cancer patients after radical hysterectomy.

    abstract：BACKGROUND:To assess the safety and efficacy of simultaneous integrated boost (SIB) or late course accelerated boost (LCAB) with external beam radiotherapy (EBRT) to the vaginal cuff for high risk cervical cancer patients after radical hysterectomy. METHODS:Between October 2009 and January 2012, patients with high ris...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/s12885-015-1248-3

    authors： Wang X,Zhao Y,Shen Y,Shu P,Li Z,Bai S,Xu F

    更新日期：2015-04-11 00:00:00

  • Low prevalence of p16-positive HPV-related head-neck cancers in Thailand: tertiary referral center experience.

    abstract：BACKGROUND:There has been a sharp rise in the incidence of human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma (OPSCC) in many countries. Patients with HPV-positive OPSCC have a more favorable prognosis compared with HPV-negative OPSCC, leading to investigation and adoption of de-escalation trea...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/s12885-019-6266-0

    authors： Nopmaneepaisarn T,Tangjaturonrasme N,Rawangban W,Vinayanuwattikun C,Keelawat S,Bychkov A

    更新日期：2019-11-06 00:00:00

  • Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland.

    abstract：BACKGROUND:Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogenous group of tumors. Findings from the phase III NETTER-1 trial showed that treatment of unresectable/metastatic progressive gastrointestinal (GI) NETs with 177Lu-Dotatate resulted in a significant improvement in progression-free su...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/s12885-020-07710-7

    authors： Smith-Palmer J,Leeuwenkamp OR,Virk J,Reed N

    更新日期：2021-01-05 00:00:00

  • Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing.

    abstract：BACKGROUND:Acute lymphoblastic leukemia (ALL), the most common childhood malignancy, is characterized by recurring structural chromosomal alterations and genetic alterations, whose detection is critical in diagnosis, risk stratification and prognostication. However, the genetic mechanisms that give rise to ALL remain p...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/s12885-020-6709-7

    authors： Zhang H,Wang H,Qian X,Gao S,Xia J,Liu J,Cheng Y,Man J,Zhai X

    更新日期：2020-03-12 00:00:00

  • EGFR copy number alterations in primary tumors, metastatic lymph nodes, and recurrent and multiple primary tumors in oral cavity squamous cell carcinoma.

    abstract：BACKGROUND:The EGFR and downstream signaling pathways play an important role in tumorigenesis in oral squamous cell carcinoma (OSCC). Gene copy number alteration is one mechanism for overexpressing the EGFR protein and was also demonstrated to be related to lymph node metastasis, tumor invasiveness and perineural invas...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/s12885-017-3586-9

    authors： Huang SF,Chien HT,Cheng SD,Chuang WY,Liao CT,Wang HM

    更新日期：2017-08-30 00:00:00

  • 3-O-Acetyloleanolic acid inhibits VEGF-A-induced lymphangiogenesis and lymph node metastasis in an oral cancer sentinel lymph node animal model.

    abstract：BACKGROUND:Sentinel lymph node metastasis is a common and early event in the metastatic process of head and neck squamous cell carcinoma (HNSCC) and is the most powerful prognostic factor for survival of HNSCC patients. 3-O-acetyloleanolic acid (3AOA), a pentacyclic triterpenoid compound isolated from seeds of Vigna si...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/s12885-018-4630-0

    authors： Hwang-Bo J,Bae MG,Park JH,Chung IS

    更新日期：2018-07-05 00:00:00

  • A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection.

    abstract：BACKGROUND:UroVysion fluorescence in situ hybridization (uFISH) was reported to have superior sensitivity to urine cytology. However uFISH studies are limited by varying definitions of what is considered a positive result, absence of histopathology and small sample size. The aim of our study was to better determine the...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/s12885-017-3227-3

    authors： Lavery HJ,Zaharieva B,McFaddin A,Heerema N,Pohar KS

    更新日期：2017-04-07 00:00:00

  • Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.

    abstract：BACKGROUND:Papillary renal cell carcinoma (pRCC) is the 2nd most frequent histological type of kidney cancer and accounts for approximately 15% of all renal cell carcinoma. It has a poorer prognosis than clear cell RCC (ccRCC) with a lack of standard treatments. CASE PRESENTATION:We report the case of a 51 year old ma...

    journal_title：BMC cancer

    pub_type： 杂志文章,评审

    doi：10.1186/s12885-018-5049-3

    authors： Rochigneux P,Thomassin-Piana J,Laibe S,Brunelle S,Salem N,Escudier B,Vassal G,Gravis G

    更新日期：2018-11-22 00:00:00

  • Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy.

    abstract：BACKGROUND:We evaluated the hierarchical risk groups for the estimated survival of WHO grade III glioma patients using recursive partitioning analysis (RPA). To our knowledge, this is the first study to address the results of RPA specifically for WHO grade III gliomas. METHODS:A total of 133 patients with anaplastic a...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/1471-2407-9-450

    authors： Park CK,Lee SH,Han JH,Kim CY,Kim DW,Paek SH,Kim DG,Heo DS,Kim IH,Jung HW

    更新日期：2009-12-18 00:00:00

  • Aberrant allele-specific replication, independent of parental origin, in blood cells of cancer patients.

    abstract：BACKGROUND:Allelic counterparts of biallelically expressed genes display an epigenetic symmetry normally manifested by synchronous replication, different from genes subjected to monoallelic expression, which normally are characterized by an asynchronous mode of replication (well exemplified by the SNRPN imprinted locus...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/1471-2407-8-390

    authors： Dotan ZA,Dotan A,Ramon J,Avivi L

    更新日期：2008-12-25 00:00:00

  • Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).

    abstract：BACKGROUND:Triple-negative breast cancer (TNBC) comprises a heterogeneous group of diseases which are generally associated with poor prognosis. Up to now, no targeted treatment beyond anti-VEGF therapy has been approved for TNBC and cytotoxic agents remain the mainstay of treatment. Ixazomib is a selective and reversib...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/s12885-018-4979-0

    authors： Rinnerthaler G,Gampenrieder SP,Petzer A,Burgstaller S,Fuchs D,Rossmann D,Balic M,Egle D,Rumpold H,Singer CF,Bartsch R,Petru E,Melchardt T,Ulmer H,Mlineritsch B,Greil R

    更新日期：2018-11-06 00:00:00

  • Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis.

    abstract：BACKGROUND:Toll-like receptors (TLRs) have garnered an extraordinary amount of interest in cancer research due to their role in tumor progression. By activating the production of several biological factors, TLRs induce type I interferons and other cytokines, which drive an inflammatory response and activate the adaptiv...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/1471-2407-10-665

    authors： González-Reyes S,Marín L,González L,González LO,del Casar JM,Lamelas ML,González-Quintana JM,Vizoso FJ

    更新日期：2010-12-03 00:00:00

  • Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer.

    abstract：BACKGROUND:Chemoresistance is one of the main problems in treatment of cancer. Periostin (PN) is a stromal protein which is mostly secreted from cancer associated fibroblasts in the tumor microenvironment and can promote cancer progression including cell survival, metastasis, and chemoresistance. The main objective of ...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/s12885-020-07761-w

    authors： Oo KK,Kamolhan T,Soni A,Thongchot S,Mitrpant C,O-Charoenrat P,Thuwajit C,Thuwajit P

    更新日期：2021-01-14 00:00:00

  • Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells.

    abstract：BACKGROUND:Triple-negative breast cancer (TNBC) has aggressive progression with poor prognosis and ineffective treatments. Selumetinib is an allosteric, ATP-noncompetitive inhibitor of MEK1/2, which has benn known as effective antineoplastic drugs for several malignant tumors. We hypothesized that Selumetinib might be ...

    journal_title：BMC cancer

    pub_type： 杂志文章

    doi：10.1186/s12885-016-2773-4

    authors： Zhou Y,Lin S,Tseng KF,Han K,Wang Y,Gan ZH,Min DL,Hu HY

    更新日期：2016-10-21 00:00:00